Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A. Ribas A, et al. Among authors: kendra kl. J Clin Oncol. 2013 Feb 10;31(5):616-22. doi: 10.1200/JCO.2012.44.6112. Epub 2013 Jan 7. J Clin Oncol. 2013. PMID: 23295794 Free PMC article. Clinical Trial.
Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy.
Johns AC, Yang M, Wei L, Grogan M, Patel SH, Li M, Husain M, Kendra KL, Otterson GA, Burkart JT, Spakowicz D, Hoyd R, Owen DH, Presley CJ. Johns AC, et al. Among authors: kendra kl. Cancer Immunol Immunother. 2023 Jul;72(7):2005-2013. doi: 10.1007/s00262-023-03371-0. Epub 2023 Feb 4. Cancer Immunol Immunother. 2023. PMID: 36738310 Free PMC article.
BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy.
Sun SH, Angell CD, Savardekar H, Sundi D, Abood D, Benner B, DiVincenzo MJ, Duggan M, Choueiry F, Mace T, Trikha P, Lapurga G, Johnson C, Carlson EJ, Chung C, Peterson BR, Lianbo Yu, Zhao J, Kendra KL, Carson WE 3rd. Sun SH, et al. Among authors: kendra kl. Cancer Immunol Immunother. 2023 Nov;72(11):3461-3474. doi: 10.1007/s00262-023-03497-1. Epub 2023 Aug 2. Cancer Immunol Immunother. 2023. PMID: 37528320 Free PMC article.
Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase.
Savardekar H, Allen C, Jeon H, Li J, Quiroga D, Schwarz E, Wu RC, Zelinskas S, Lapurga G, Abreo A, Stiff A, Shaffer J, Blaser BW, Old M, Wesolowski R, Xin G, Kendra KL, Chung D, Carson WE 3rd. Savardekar H, et al. Among authors: kendra kl. Mol Cancer Res. 2024 Mar 1;22(3):308-321. doi: 10.1158/1541-7786.MCR-22-0572. Mol Cancer Res. 2024. PMID: 38015751
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, Eickhoff J, Kendra K, Reisfeld R, Gillies SD, Sondel P. King DM, et al. J Clin Oncol. 2004 Nov 15;22(22):4463-73. doi: 10.1200/JCO.2004.11.035. Epub 2004 Oct 13. J Clin Oncol. 2004. PMID: 15483010 Free PMC article. Clinical Trial.
A pilot study of bevacizumab and interferon-α2b in ocular melanoma.
Guenterberg KD, Grignol VP, Relekar KV, Varker KA, Chen HX, Kendra KL, Olencki TE, Carson WE 3rd. Guenterberg KD, et al. Among authors: kendra kl. Am J Clin Oncol. 2011 Feb;34(1):87-91. doi: 10.1097/COC.0b013e3181d2ed67. Am J Clin Oncol. 2011. PMID: 20458209 Free PMC article. Clinical Trial.
93 results